Dr. Geyer is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
6445 Main St
Floor 24
Houston, TX 77030Phone+1 713-441-9948Fax+1 713-441-8791- Is this information wrong?
Education & Training
Baylor College of MedicineFellowship, Hematology and Medical Oncology, 1984 - 1986- Baylor College of MedicineFellowship, Hematology, 1984 - 1984
- Baylor College of MedicineResidency, Internal Medicine, 1980 - 1983
Texas Tech University Health Sciences Center School of MedicineClass of 1980
Certifications & Licensure
PA State Medical License 2002 - 2024
TX State Medical License 1980 - 2024
VA State Medical License 2013 - 2024
FL State Medical License 2013 - 2015- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
- National Board of Physicians and Surgeons Internal Medicine
- National Board of Physicians and Surgeons Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer Start of enrollment: 2014 Apr 22
- Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer Start of enrollment: 2019 Apr 05
Publications & Presentations
PubMed
- 11 citationsMatched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness.Otto Metzger-Filho, Katharine Collier, Sarah Asad, Peter Ansell, Mark A. Watson, Junu Bae, Mathew Cherian, Joyce O'Shaughnessy, Michael Untch, Hope S. Rugo, Jens Huobe...> ;NPJ Breast Cancer. 2021 Nov 11
- 21-Gene Recurrence Score Predictive for Patients Most Likely to Benefit From Postoperative Radiation Following Breast Conserving Surgery for T1N0 Breast Cancer.Neil Chevli, Waqar Haque, K.T. Tran, Andrew M. Farach, Mary R. Schwartz, Charles E. Geyer, Sandra S. Hatch, Edward Brian Butler, B.S. Teh> ;International Journal of Radiation Oncology Biology Physics. 2021 Nov 1
- 111 citationsTrastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trialsRosie Bradley, Jeremy P Braybrooke, Richard Gray, Robert Kerrin Hills, Z Liu, Richard Peto, Lucy Davies, David Dodwell, Paul McGale, Hongchao Pan, Carolyn W. Taylor, S...> ;The Lancet. Oncology. 2021 Aug 1
- Join now to see all
Journal Articles
- Association of Immunophenotype with Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast CancerCharles E Geyer, William M Sikov, JAMA Oncology
Lectures
- NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with ...2019 ASCO Annual Meeting - 6/1/2019
- NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in Patients (pts) with ...2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Press Mentions
Breast-Cancer Pill Reduced Recurrence, Death in Early-Stage Patients, Study FindsJune 3rd, 2021
Not All Node-Positive Breast Cancers Benefit from ChemotherapyAugust 13th, 2019
Substituting Adjuvant Trastuzumab Emtansine for Herceptin Improves Survival in Patients with Human Epidermal Growth Factor Receptor 2–Positive Breast CancerApril 1st, 2019- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
Houston Methodist HospitalHouston, Texas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
